GSK’s Nucala Application for COPD Accepted for Review in China

GlaxoSmithKline ( (GB:GSK) ) has shared an announcement.

GSK announced that the China National Medical Products Administration has accepted the review of its new drug application for Nucala (mepolizumab) as an add-on treatment for COPD with an eosinophilic phenotype. The submission is supported by data from the MATINEE trial, which demonstrated significant reductions in exacerbations among a broad population of COPD patients. If approved, Nucala could become the first approved biologic with monthly dosing for COPD, potentially offering a new treatment option for a significant portion of the 100 million people with COPD in China.

More about GlaxoSmithKline

GSK is a global biopharma company focused on uniting science, technology, and talent to advance healthcare. It has a leading position in respiratory medicine with a comprehensive portfolio of vaccines, targeted biologics, and inhaled medicines aimed at improving outcomes for patients with respiratory diseases like asthma and COPD.

YTD Price Performance: 6.76%

Average Trading Volume: 7,365,639

Technical Sentiment Consensus Rating: Sell

Current Market Cap: £58.9B

Learn more about GSK stock on TipRanks’ Stock Analysis page.